CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th.

CytomX Therapeutics Stock Performance

CTMX opened at $0.84 on Tuesday. The company has a market capitalization of $65.74 million, a PE ratio of 4.94 and a beta of 1.03. The stock’s fifty day moving average is $1.04 and its 200-day moving average is $1.15. CytomX Therapeutics has a one year low of $0.79 and a one year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. During the same period in the previous year, the business earned $0.04 earnings per share. On average, equities research analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Trading of CytomX Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. raised its holdings in shares of CytomX Therapeutics by 32.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after acquiring an additional 405,669 shares during the period. Sei Investments Co. acquired a new stake in CytomX Therapeutics during the 2nd quarter valued at $467,000. Virtu Financial LLC purchased a new stake in shares of CytomX Therapeutics in the third quarter valued at $104,000. Congress Park Capital LLC boosted its position in shares of CytomX Therapeutics by 5.4% in the third quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock worth $1,435,000 after buying an additional 62,788 shares during the period. Finally, XTX Topco Ltd grew its holdings in shares of CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.